TECLens, Inc. raises $9.3 million in Series A round for refractive technology

(Image Credit: AdobeStock)

TECLens, Inc. has secured $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. Additional investors in the company include Rimonci Capital and Sunmed Capital.

According to the company’s press release¹, the funding is allocated to support the clinical development of its non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Also in the release¹, Thomas Dunlap, CEO of TECLens, said that he saw this funding as, “a powerful endorsement of both our quantitative corneal cross-linking technology and our mission to deliver a non-invasive and cost-effective refractive treatment for millions of people with vision disorders. We're honored by their support and view this as a strong validation of our innovative approach to addressing both refractive and therapeutic unmet needs in eye care.”

Traditional CXL uses riboflavin and ultraviolet light to strengthen the cornea. TECLens’ use a proprietary Quantitative Corneal Cross-Linking (qCXL), which the company says is designed to deliver a pre-calculated pattern and dose of UV light based on a computational biomechanics model of each patient’s eye.¹

The device was designed for use in the exam room and has been successfully demonstrated in eyes with keratoconus. In addition, TECLens is advancing clinical studies for refractive correction, with a primary focus on presbyopia. Potential future applications include pediatric progressive myopia, low-order adult myopia, hyperopia, and astigmatism.¹

Reference:

1. TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology. TECLens, Inc. February 11, 2025. Accessed February 12, 2025. https://www.businesswire.com/news/home/20250211268409/en/TECLens-Secures-9.3-Million-Series-A-Funding-to-Advance-Its-Non-Invasive-Refractive-Technology